In August 2020, the World Health Organization (WHO) devised a strategy for the elimination of cervical cancer. Per this strategy, all countries across the region must focus on reaching and maintaining an incidence rate of less than 4 per 100,000 women to eliminate cervical cancer. To attain such low incidence rates, countries should focus on cervical cancer screening, treatment, and vaccination. Medicare, a popular government insurance program, provides coverage for PAP tests, pelvic exams, and clinical breast examinations performed every two years for cervical cancer screening.
Unitaid, a global health agency that works to bring about innovative solutions to prevent, diagnose, and treat major diseases in low- and middle-income countries, has come up with a new initiative for cervical cancer prevention. Its efforts are focused on expanding access to critical tools and services to screen for the early signs of cervical cancer, followed by the treatment of positive cases. Unitaid is providing support for the Clinton Health Access Initiative (CHAI) and the Scale Up Cervical Cancer Elimination with Secondary Prevention Strategy (SUCCESS) Project, which are being carried out in partnership with Expertise France, Jhpiego, and the Union for International Cancer Control (UICC). Unitaid is collaborating with these partners and governments of 14 low- and middle-income countries to develop an affordable and highly effective package of tools, which can help the World Health Organization achieve its cervical cancer elimination targets. The Unitaid has invested ~US$ 70 million in innovative tools to screen women living in low-resource environments for precancer conditions and treat them. In 14 countries, Unitaid is striving to overcome access barriers and laying the groundwork for national cervical cancer elimination efforts, demonstrating effective models of prevention across low- and middle-income countries.
Such initiatives by various healthcare organizations and governments for preventing cervical cancer boost the growth of the CIN & HR-HPV treatment market.
The South America CIN and HR-HPV Treatment market is segmented into Argentina, Brazil, and the Rest of South & Central America. The market growth in this region is attributed to the increasing prevalence of cervical cancer caused by HR-HPV infections and surging initiatives by governments to eliminate cervical cancers.
South America CIN & HR-HPV Treatment Market Segmentation
The South America CIN & HR-HPV treatment market is segmented into disease type, strain type, offering, product type, end user, and country.
Based on disease type, the market is segmented into cervical intraepithelial neoplasia 1 (CIN 1), cervical intraepithelial neoplasia 2 (CIN 2), and cervical intraepithelial neoplasia 3 (CIN 3). The cervical intraepithelial neoplasia 3 (CIN 3) segment registered the largest market share in 2023.
Based on strain type, the market is segmented into HPV 16, HPV 18, and others. The HPV 16 segment held the largest market share in 2023.
Based on offering, the market is bifurcated into diagnostic methods and treatments. The treatments segment held a larger market share in 2023. Further, diagnostic methods are segmented into pap smear, HPV testing, colposcopy, and biopsy. Further, treatments are bifurcated into excision surgery and ablation techniques.
Based on product type, the market is segmented into kits & reagents, instruments, and services. The services segment held the largest market share in 2023.
Based on end user, the market is segmented into hospitals & clinics, diagnostic laboratories, specialized clinical laboratories, and others. The hospitals & clinics segment held the largest market share in 2023.
Based on country, the market is segmented into Brazil Argentina, and the Rest of South America. Brazil dominated the market share in 2023.
Fujirebio Europe NV; Qiagen NV; Abbott Laboratories; F. Hoffmann-LA Roche Ltd; and Thermo Fisher Scientific Inc are the leading companies operating in the CIN & HR-HPV treatment market in the region.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 490.90 Million |
| Market Size by 2028 | US$ 659.12 Million |
| CAGR (2023 - 2028) | 6.1% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2028 |
| Segments Covered |
By Disease Type
|
| Regions and Countries Covered |
South and Central America
|
| Market leaders and key company profiles |
|
The South America CIN & HR-HPV Treatment Market is valued at US$ 490.90 Million in 2023, it is projected to reach US$ 659.12 Million by 2028.
As per our report South America CIN & HR-HPV Treatment Market, the market size is valued at US$ 490.90 Million in 2023, projecting it to reach US$ 659.12 Million by 2028. This translates to a CAGR of approximately 6.1% during the forecast period.
The South America CIN & HR-HPV Treatment Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South America CIN & HR-HPV Treatment Market report:
The South America CIN & HR-HPV Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South America CIN & HR-HPV Treatment Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South America CIN & HR-HPV Treatment Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South America CIN & HR-HPV Treatment Market
